相关实验视频
Updated: Sep 12, 2025
08:53
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
Published on: August 31, 2016
15.4K
年轻的非亲属捐赠者与较大的兄弟姐妹相比,为患有髓状瘤的患者提供了生存优势
Johannes Schetelig1,2, Henning Baldauf3, Carina Rave3
1Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany. johannes.schetelig@ukdd.de.
Leukemia
|August 6, 2025
概括
年轻的,与HLA相容的非亲属捐赠者 (UD) 与较老的匹配兄弟捐赠者 (MSD) 相比,改善了接受异构造血细胞移植 (alloHCT) 的老年患者的生存率,并降低了复发风险. 这一发现支持使用较年轻的UD在所有HCT中用于骨髓性恶性瘤.
科学领域:
- 血液学 血液学 血液学
- 移植免疫学 移植免疫学
- 在瘤学瘤学.
背景情况:
- 捐赠者的年龄是优化全源造血细胞移植 (alloHCT) 结果的关键因素.
- 老年患有骨髓瘤恶性瘤的患者在寻找合适的捐赠者方面经常面临挑战.
研究的目的:
- 调查年轻的无血缘捐赠者 (UD) 与HLA相同的兄弟捐赠者 (MSD) 相比,对于患有骨髓瘤的老年患者 (≥50岁) 提供生存益处.
主要方法:
- 在3460名患者 (≥50岁) 的回顾性注册表研究中,他们接受了第一个alloHCT (2010-2020年).
- 从MSD (≥50年) 获得alloHCT的患者与与HLA相容的UD (≤35年) 之间的无事件生存 (EFS),总生存 (OS) 和复发风险的比较.
- 对9905名患有骨髓瘤恶性瘤的患者进行了分析,以证实研究结果.
主要成果:
- 多变量分析显示,与MSD相比,HLA兼容的UD显著改善EFS (HR 0.86),OS (HR 0.82) 和降低复发风险 (HR 0.84),与MSD相比.
- 当UD具有不利的性别或CMV状态与具有有利星座的MSD相比时,没有观察到生存优势.
- 分析证实,复发风险降低 (汇总HR 0.78) 和更好的EFS (汇总HR 0.89),与年轻匹配的UD与MSD相比.
结论:
- 选择年轻的,与HLA相容的无血缘捐赠者,而不是老年匹配的兄弟捐赠者,可以提高存活率,并降低接受alloHCT的老年骨髓瘤恶性病患者的复发风险.
- 这一策略可以优化对需要alloHCT的老年患者的供体选择.
相关概念视频
01:22Bone Marrow Sampling and Transplants
500
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
500
01:28Kidney Transplant I: Introduction
60
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
60
01:21Stem Cell Therapy for Tissue Regeneration
4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
01:15Differentiation of Common Myeloid Progenitor Cells
3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K